High Anti-Infliximab Antibody Titers Do Not Impact Response to Subsequent Adalimumab Treatment in Inflammatory Bowel Diseases. Sasson AN, Ananthakrishnan AN. Dig Dis Sci 2022;67:3124-3128.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sasson AN, Ananthakrishnan AN. High Anti-Infliximab Antibody Titers Do Not Impact Response to Subsequent Adalimumab Treatment in Inflammatory Bowel Diseases. Dig Dis Sci 2022;67:3124-3128.
PMID: 34117949